Literature DB >> 25851811

Cyst infection in autosomal dominant polycystic kidney disease: causative microorganisms and susceptibility to lipid-soluble antibiotics.

T Suwabe1, H Araoka, Y Ubara, K Kikuchi, R Hazue, K Mise, S Hamanoue, T Ueno, K Sumida, N Hayami, J Hoshino, A Imafuku, M Kawada, R Hiramatsu, E Hasegawa, N Sawa, K Takaichi.   

Abstract

Cyst infection is a frequent and serious complication of autosomal dominant polycystic kidney disease (ADPKD). Lipid-soluble antibiotics like fluoroquinolones show good penetration into cysts and are recommended for cyst infection, but causative microorganisms are often resistant to these agents. This study investigated the profile of the microorganisms causing cyst infection in ADPKD, their susceptibility to lipid-soluble antibiotics, and clinical outcomes. This retrospective study reviewed all ADPKD patients admitted to Toranomon Hospital with a diagnosis of cyst infection from January 2004 to March 2014. All patients who underwent cyst drainage and had positive cyst fluid cultures were enrolled. Patients with positive blood cultures who satisfied our criteria for cyst infection or probable infection were also enrolled. There were 99 episodes with positive cyst fluid cultures and 93 episodes with positive blood cultures. The majority of patients were on dialysis. The death rate was high when infection was caused by multiple microorganisms or when there were multiple infected cysts. Gram-negative bacteria accounted for 74-79 % of the isolates in all groups, except for patients with positive hepatic cyst fluid cultures. The susceptibility of Escherichia coli to fluoroquinolones was very low in patients with hepatic cyst infection, especially those with frequent episodes and those with hepatomegaly. Fungi were detected in two episodes. Fluoroquinolone-resistant microorganisms showed a high prevalence in cyst infection. It is important to identify causative microorganisms to avoid the overuse of fluoroquinolones and to improve the outcome of cyst infection in ADPKD.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25851811     DOI: 10.1007/s10096-015-2361-6

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  20 in total

1.  Positron-emission computed tomography in cyst infection diagnosis in patients with autosomal dominant polycystic kidney disease.

Authors:  François Jouret; Renaud Lhommel; Claire Beguin; Olivier Devuyst; Yves Pirson; Ziad Hassoun; Nada Kanaan
Journal:  Clin J Am Soc Nephrol       Date:  2011-06-23       Impact factor: 8.237

2.  Percutaneous cyst puncture in the treatment of cyst infection in autosomal dominant polycystic kidney disease.

Authors:  A B Chapman; D Thickman; P A Gabow
Journal:  Am J Kidney Dis       Date:  1990-09       Impact factor: 8.860

3.  Nationwide survey of antibacterial activity against clinical isolates from urinary tract infections in Japan (2008).

Authors:  Tetsuro Matsumoto; Ryoichi Hamasuna; Kiyohito Ishikawa; Satoshi Takahashi; Mitsuru Yasuda; Hiroshi Hayami; Kazushi Tanaka; Hiroshi Kiyota; Tetsuro Muratani; Koichi Monden; Soichi Arakawa; Shingo Yamamoto
Journal:  Int J Antimicrob Agents       Date:  2011-01-16       Impact factor: 5.283

4.  Infected hepatic and renal cysts: differential impact on outcome in autosomal dominant polycystic kidney disease.

Authors:  Tatsuya Suwabe; Yoshifumi Ubara; Yasushi Higa; Shohei Nakanishi; Yoko Sogawa; Kazufumi Nomura; Hiroaki Nishimura; Jyunichi Hoshino; Naoki Sawa; Hideyuki Katori; Fumi Takemoto; Michio Nakamura; Shinji Tomikawa; Shigeko Hara; Kenmei Takaichi
Journal:  Nephron Clin Pract       Date:  2009-04-24

5.  Penetration of trimethoprim and sulfamethoxazole into cysts in a patient with autosomal-dominant polycystic kidney disease.

Authors:  S J Schwab; M E Weaver
Journal:  Am J Kidney Dis       Date:  1986-05       Impact factor: 8.860

6.  Ciprofloxacin activity in cyst fluid from polycystic kidneys.

Authors:  L W Elzinga; T A Golper; A L Rashad; M E Carr; W M Bennett
Journal:  Antimicrob Agents Chemother       Date:  1988-06       Impact factor: 5.191

7.  Renal infection in autosomal dominant polycystic kidney disease.

Authors:  S J Schwab; S J Bander; S Klahr
Journal:  Am J Med       Date:  1987-04       Impact factor: 4.965

8.  PH-dependent accumulation of clindamycin in a polycystic kidney.

Authors:  S Schwab; D Hinthorn; D Diederich; F Cuppage; J Grantham
Journal:  Am J Kidney Dis       Date:  1983-07       Impact factor: 8.860

9.  Cyst infections in patients with autosomal dominant polycystic kidney disease.

Authors:  Marion Sallée; Cédric Rafat; Jean-Ralph Zahar; Benoît Paulmier; Jean-Pierre Grünfeld; Bertrand Knebelmann; Fadi Fakhouri
Journal:  Clin J Am Soc Nephrol       Date:  2009-05-21       Impact factor: 8.237

10.  Trimethoprim-sulfamethoxazole in cyst fluid from autosomal dominant polycystic kidneys.

Authors:  L W Elzinga; T A Golper; A L Rashad; M E Carr; W M Bennett
Journal:  Kidney Int       Date:  1987-12       Impact factor: 10.612

View more
  15 in total

1.  Diagnostic utility of 18FDG-PET/CT for ADPKD cyst infection.

Authors:  Yoshinosuke Shimamura; Hideki Takizawa
Journal:  Clin Exp Nephrol       Date:  2017-09-14       Impact factor: 2.801

2.  Bilateral Nephrectomy in Patients with Autosomal Dominant Polycystic Kidney Disease and End-Stage Chronic Renal Failure.

Authors:  Alexander E Lubennikov; Nicolay V Petrovskii; German E Krupinov; Evgeniy M Shilov; Roman N Trushkin; Oleg N Kotenko; Petr V Glybochko
Journal:  Nephron       Date:  2021-02-05       Impact factor: 2.847

Review 3.  Polycystic Liver Disease: Pathophysiology, Diagnosis and Treatment.

Authors:  Luiz Fernando Norcia; Erika Mayumi Watanabe; Pedro Tadao Hamamoto Filho; Claudia Nishida Hasimoto; Leonardo Pelafsky; Walmar Kerche de Oliveira; Ligia Yukie Sassaki
Journal:  Hepat Med       Date:  2022-09-29

Review 4.  New treatment paradigms for ADPKD: moving towards precision medicine.

Authors:  Matthew B Lanktree; Arlene B Chapman
Journal:  Nat Rev Nephrol       Date:  2017-10-09       Impact factor: 28.314

5.  Hepatic Cyst Infection During Use of the Somatostatin Analog Lanreotide in Autosomal Dominant Polycystic Kidney Disease: An Interim Analysis of the Randomized Open-Label Multicenter DIPAK-1 Study.

Authors:  Marten A Lantinga; Hedwig M A D'Agnolo; Niek F Casteleijn; Johan W de Fijter; Esther Meijer; Annemarie L Messchendorp; Dorien J M Peters; Mahdi Salih; Edwin M Spithoven; Darius Soonawala; Folkert W Visser; Jack F M Wetzels; Robert Zietse; Joost P H Drenth; Ron T Gansevoort
Journal:  Drug Saf       Date:  2017-02       Impact factor: 5.606

6.  Prognostic impact of peritonitis in hemodialysis patients: A national-wide longitudinal study in Taiwan.

Authors:  Yueh-An Lu; Kun-Hua Tu; Cheng-Chia Lee; Patricia W Wu; Chee-Jen Chang; Ya-Chung Tian; Chih-Wei Yang; Pao-Hsien Chu
Journal:  PLoS One       Date:  2017-03-16       Impact factor: 3.240

Review 7.  Cyst infection in autosomal dominant polycystic kidney disease: our experience at Toranomon Hospital and future issues.

Authors:  Tatsuya Suwabe
Journal:  Clin Exp Nephrol       Date:  2020-07-22       Impact factor: 2.801

8.  Intracystic magnetic resonance imaging in patients with autosomal dominant polycystic kidney disease: features of severe cyst infection in a case-control study.

Authors:  Tatsuya Suwabe; Yoshifumi Ubara; Toshiharu Ueno; Noriko Hayami; Junichi Hoshino; Aya Imafuku; Masahiro Kawada; Rikako Hiramatsu; Eiko Hasegawa; Naoki Sawa; Satoshi Saitoh; Itsuko Okuda; Kenmei Takaichi
Journal:  BMC Nephrol       Date:  2016-11-09       Impact factor: 2.388

9.  Infected renal cyst presented with pleural effusion in a woman with autosomal dominant polycystic kidney disease.

Authors:  Ester Casillas-Sagrado; Victor Burguera; Maria Eugenia Rioja-Martín; Maite Rivera-Gorrín
Journal:  Clin Kidney J       Date:  2017-08-31

10.  Cyst infection in autosomal dominant polycystic kidney disease: penetration of meropenem into infected cysts.

Authors:  Satoshi Hamanoue; Tatsuya Suwabe; Yoshifumi Ubara; Koichi Kikuchi; Ryo Hazue; Koki Mise; Toshiharu Ueno; Kenmei Takaichi; Kana Matsumoto; Kunihiko Morita
Journal:  BMC Nephrol       Date:  2018-10-19       Impact factor: 2.388

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.